Heart device maker Edwards Lifesciences Corp. says it expects a sales boost from new and current products to drive double-digit earnings growth in 2010.
The company says it expects profit between $3.50 and $3.60 per share on revenue between $1.43 billion and $1.5 billion in 2010. The outlook represents up to 18 percent growth in earnings per share.
Analysts polled by Thomson Reuters expect $3.53 per share in profit on $1.42 billion in revenue in 2010.
The company says it expects to launch its new Sapien XT transcatheter valve in Europe during the first quarter. Meanwhile, it says recent product launches have been driving surgical valve sales and the momentum is expected to continue into 2010.
Latest from Today's Medical Developments
- Boston Scientific to acquire Penumbra, expanding cardiovascular portfolio
- Star Cutter introduces Double Pilot Reamer
- #80 Manufacturing Matters - Machining Strategies to Save Time and Improve your Process for MedTech Components with Kennametal Inc.
- Real-world parts and expert manufacturing advice
- Experts discuss the latest in toolholding technology
- How permanent magnets are powering medical innovation
- Forecasting the year ahead in design and manufacturing
- Tecomet, Orchid Orthopedic Solutions announce merger agreement
